Overview

Extension Study of Bomedemstat (IMG-7289) in Patients With Myeloproliferative Neoplasms

Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in patients with an MPN who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102 and IMG-7289-CTP-201 (referred to hereafter as 'feeder studies').
Phase:
Phase 2
Details
Lead Sponsor:
Imago BioSciences,Inc.